What labels actually report
The current Wegovy and Zepbound prescribing information report mean changes in pancreatic enzymes in specific trials. Each label says the clinical significance of lipase or amylase elevations is unknown in the absence of other signs and symptoms of pancreatitis. [1] [2]
Wegovy label
Weight-reduction trials
- Mean amylase increase
- 15%–16%
- Mean lipase increase
- 39%
These changes were not observed in placebo. [1]
Zepbound label
Pooled Studies 1 and 2
- Mean pancreatic amylase increase
- 20%–25% vs 2.1% placebo
- Mean lipase increase
- 28%–35% vs 5.8% placebo
Why one result is not a diagnosis
The Revised Atlanta international consensus requires two of three criteria for an acute pancreatitis diagnosis. [4]
- Criterion 1
Characteristic abdominal pain
- Criterion 2
Lipase or amylase at least 3× the upper limit of normal
- Criterion 3
Characteristic imaging
A single mild enzyme elevation alone does not meet this consensus definition. These criteria are educational, not instructions for self-diagnosis or interpretation of an individual result. [4]
What LEADER adds—and does not
LEADER randomized 9,340 adults with type 2 diabetes and high cardiovascular risk to liraglutide or placebo, with a median observation period of 3.84 years. Liraglutide increased lipase by 28% and amylase by 7%. [3]
Enzyme elevations did not predict subsequent acute pancreatitis; the reported positive predictive value was under 1%. [3]
Label warning symptoms deserve prompt medical evaluation
The Wegovy label warns that acute pancreatitis has been observed with GLP-1 receptor agonists including Wegovy. Both labels describe persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting. [1] [2]
These warning symptoms are a reason for prompt medical evaluation. Medication decisions—including whether to alter or discontinue a medicine—belong with the prescriber and the current product label.
A neutral record for a prescriber
A dated record can preserve context without assigning meaning or cause:
Copy it as printed.
Name, value, unit, reference range, and date.
Use the person’s own words and include the onset date.
Keep relevant dates together.
Preserve questions for the clinician.
A tracker preserves context. It cannot diagnose, interpret, or determine causation.
Evidence boundary: what not to infer
Questions to bring to a clinician
- How should this result be interpreted with symptoms and the reference range?
- Is repeat testing or other evaluation relevant?
- What label-specific context matters?
- Which changes warrant more urgent contact?
Keep the context dated
Keep your protocol timeline legible
Jabbit can keep injection history and reminders organized, so you can bring a dated protocol timeline alongside the original lab report. It cannot diagnose, interpret results, or determine causation.
Track your protocol in JabbitFrequently asked questions
Does an elevated amylase or lipase result diagnose pancreatitis?
No. The Revised Atlanta international consensus requires two of three criteria for acute pancreatitis: characteristic abdominal pain; lipase or amylase at least three times the upper limit of normal; or characteristic imaging. A single mild enzyme elevation alone does not meet that consensus definition. [4]
Can Wegovy or Zepbound raise amylase or lipase?
Their labels report mean pancreatic enzyme increases in studied treatment groups. The labels say the clinical significance is unknown without other signs and symptoms of pancreatitis. [1] [2]
Did enzyme elevations predict acute pancreatitis in LEADER?
No. The reported positive predictive value was under 1%. This finding is limited to the trial’s liraglutide-specific population. [3]
Sources
- [1]Current Novo Nordisk Wegovy prescribing information.
- [2]Current Eli Lilly Zepbound prescribing information.
- [3]LEADER randomized trial, PubMed PMID 28476871.
- [4]Revised Atlanta international consensus, PubMed PMID 23100216; full text.
Sources checked August 26, 2026.